Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 5/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 2/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6247183 | 0.88 | ITK (0.39) | ITKRAB9AADORA2AHTTHSD17B10 | |
| SCHEMBL7886984 | 0.85 | RAB9A (0.43) | RAB9A | |
| SCHEMBL3729573 | 0.83 | RAB9A (0.42) | ITKPDE2ARAB9AGRM2 | |
| SCHEMBL13041706 | 0.83 | RAB9A (0.39) | RAB9A | |
| SCHEMBL6218617 | 0.83 | MAPT (0.39) | ITKRAB9AADORA2AHTTHSD17B10 | |
| SCHEMBL6241622 | 0.82 | CNR2 (0.47) | — | |
| SCHEMBL7893298 | 0.81 | PDE2A (0.42) | PDE2AADORA2AGRM2IDH1 | |
| SCHEMBL6489644 | 0.78 | SMN1; SMN2 (0.43) | ITKRAB9AADORA2A | |
| SCHEMBL6489831 | 0.77 | ADORA2A (0.43) | ITKRAB9AADORA2A | |
| SCHEMBL31069442 | 0.71 | NTRK1 (0.52) | NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | ASTRAZENECA UK LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | ASTRAZENECA UK LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| WO-2010103306-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS ANTIVARAL AGENTS | ASTRAZENECA UK LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | RB1, RPP30, SARS1 | ITK 4032/4885PDE2A 4217/4885RAB9A 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.